Selected discussion
Cronus Pharma Launches First FDA-Approved Bioequivalent Robenacoxib Injection for Veterinary Use
Industry development with potential relevance for veterinary professionals, companion animal care, and animal health stakeholders.
Digital tools are becoming increasingly important across veterinary medicine, from clinical workflows to client communication and practice operations.
According to the announcement, Cronus Pharma Launches First FDA-Approved Bioequivalent Robenacoxib Injection for Veterinary Use. The development is relevant because it reflects how animal health companies, service providers, and technology platforms are responding to changing expectations in veterinary care.
What Was Announced
EAST BRUNSWICK, N.J.--( BUSINESS WIRE )-- Cronus Pharma LLC, a veterinary pharmaceutical company focused on developing high-quality, cost-effective animal health products, today announced the U.S. launch of Robenacoxib Injection, the only FDA-approved bioequivalent to ONSIOR ® (robenacoxib) Injection. First bioequivalent to ONSIOR® (robenacoxib) Injection equips veterinarians with new, cost-effective NSAID (no…
Discussion thread
Community replies
Follow the line down to read the conversation in order.
No replies yet
No replies yet. Be the first professional to join this discussion.
Use the reply box above to start the conversation.
Join this discussion
Add your reply
Share a professional insight, ask a focused question, or add relevant clinical experience.
Member participation
Log in to join the discussion
Share an answer, ask a question, reply to another professional, or mark useful contributions as helpful.